HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer

Overview of attention for article published in JAMA Oncology, April 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

news: 2 news outlets
twitter: 66 X users

facebook: 3 Facebook pages
googleplus: 1 Google+ user

Readers on

mendeley: 52 Mendeley

So far, Altmetric has seen 6 public wall posts from 3 users.

JAMA Oncology, 01 May 2018

This study compared response to ketoconazole treatment among patients with castration-resistant prostate cancer who had 0, 1…

JAMA Oncology, 24 Oct 2017

This study compared response to ketoconazole treatment among patients with castration-resistant prostate cancer who had 0, 1…

JAMA Oncology, 15 Oct 2017

This study compared response to ketoconazole treatment among patients with castration-resistant prostate cancer who had 0, 1…

Förderverein Hilfe bei Prostatakrebs e.V., 13 Oct 2017

This study of 90 men with prostate cancer reveals that patients with the HSD3B1 (1245C) variant allele, associated with…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 2 additional Facebook posts.